抗磷脂抗体和抗磷脂综合征的风险因素。

IF 3.6 2区医学 Q2 HEMATOLOGY Seminars in thrombosis and hemostasis Pub Date : 2024-09-01 Epub Date: 2024-01-16 DOI:10.1055/s-0043-1776910

Rodrigo Aguirre Del-Pino, Rory C Monahan, Tom W J Huizinga, Jeroen Eikenboom, Gerda M Steup-Beekman

{"title":"抗磷脂抗体和抗磷脂综合征的风险因素。","authors":"Rodrigo Aguirre Del-Pino, Rory C Monahan, Tom W J Huizinga, Jeroen Eikenboom, Gerda M Steup-Beekman","doi":"10.1055/s-0043-1776910","DOIUrl":null,"url":null,"abstract":"Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"817-828"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome.\",\"authors\":\"Rodrigo Aguirre Del-Pino, Rory C Monahan, Tom W J Huizinga, Jeroen Eikenboom, Gerda M Steup-Beekman\",\"doi\":\"10.1055/s-0043-1776910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.\",\"PeriodicalId\":21673,\"journal\":{\"name\":\"Seminars in thrombosis and hemostasis\",\"volume\":\" \",\"pages\":\"817-828\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in thrombosis and hemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0043-1776910\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in thrombosis and hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0043-1776910","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

血清抗磷脂抗体（aPL）的持续存在与动脉和静脉血栓形成的高风险以及妊娠并发症有关。由于抗磷脂抗体的存在可能导致发病率和死亡率，因此，识别和认识抗磷脂抗体携带者发生抗磷脂抗体和血栓形成的风险因素有助于预防和减轻疾病负担。aPL 发生和 aPL 相关血栓形成的病理机制涉及多种因素，如遗传、恶性肿瘤和感染。本综述将探讨众所周知的风险因素及其演变，以及包括 COVID-19 在内的新风险因素在 aPL 发展和 aPL 携带者血栓形成中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome.

Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in thrombosis and hemostasis 医学-外周血管病

CiteScore

8.80

自引率

21.10%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Seminars in Thrombosis and Hemostasis is a topic driven review journal that focuses on all issues relating to hemostatic and thrombotic disorders. As one of the premiere review journals in the field, Seminars in Thrombosis and Hemostasis serves as a comprehensive forum for important advances in clinical and laboratory diagnosis and therapeutic interventions. The journal also publishes peer reviewed original research papers. Seminars offers an informed perspective on today''s pivotal issues, including hemophilia A & B, thrombophilia, gene therapy, venous and arterial thrombosis, von Willebrand disease, vascular disorders and thromboembolic diseases. Attention is also given to the latest developments in pharmaceutical drugs along with treatment and current management techniques. The journal also frequently publishes sponsored supplements to further highlight emerging trends in the field.